Thu, 05th Nov 2020 07:05
Nov 5 (Reuters) - AstraZeneca, the British drugmaker
working on one of the world's leading COVID-19 vaccine
candidates, on Thursday beat third-quarter sales estimates on
strong demand for its diverse portfolio of drugs during COVID-19
pandemic lockdowns and maintained its 2020 forecasts.
(Reporting by Pushkala Aripaka, Ludwig Burger in Frankfurt;
Editing by Bernard Orr)
(Alliance News) - AstraZeneca PLC said that, following further positive findings in clinical trial, Tagrisso has been recommended for use in the Europ...
(Sharecast News) - AstraZeneca has announced that its Tagrisso treatment for advanced lung cancer, when combined with chemotherapy, has been recommend...
June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu slows the progression of breast cancer by about five months in women whose disease worse...
June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu was shown in a large trial to delay the growth of hormone-sensitive breast cancer by abo...
(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and on Wednesday:
Astrazeneca (AZN)